Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy “The COMBO – DN” (Combination vs Monotherapy of Pregabalin and duloxetine in Diabetic Neuropathy).
Year: 2012
Type: Pharmaceutical - Pain
Phase: IIIb
Indication: Painful Diabetic Neuropathy
A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate improvement in symptoms of constipation and noninferiority in analgesic efficacy in subjects with non-malignant or malignant pain that requires around-the-clock opioid therapy taking 50/25 – 80/40 mg twice daily as oxycodone/naloxone prolonged release (OXN PR) tablets compared to subjects taking 50 – 80 mg twice daily oxycodone prolonged release (OxyPR) tablets alone.
Year: 2012
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A Phase I/IIa, Multicenter, Open-label, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration.
Year: 2013
Type: Pharmaceutical - Pain
Phase: I, IIa
Indication: Back and/or Leg Pain
A Randomized, Double-Blind, Crossover, Phase IIa Study Comparing a Single-Application TPM®/Oxycodone Patch versus Vehicle Patch in the Topical Treatment of Patients with Postherpetic Neuralgia.
Year: 2015
Type: Pharmaceutical - Pain
Phase: IIa
Indication: Postherpetic Neuralgia
CREATE-1: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects with Complex Regional Pain Syndrome Type I (CRPS-I).
Year: 2016
Type: Pharmaceutical - Pain
Phase: III
Indication: CRPS
A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of topical Lidocaine Spray in Patients with Postherpetic Neuralgia.
Year: 2018
Type: Pharmaceutical - Pain
Phase: II
Indication: Postherpetic Neuralgia
A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE).
